Latest News
Photocure study supports cost-effectiveness of blue light cystoscopy
4 May 2026 - Norwegian bladder cancer company Photocure ASA (OSE: PHO) announced on Monday the publication of a new health economic methodology in The Journal of Medical Economics demonstrating that blue light cystoscopy is cost-effective compared wi...
Apotex receives Health Canada approval for a generic Ozempic equivalent
4 May 2026 - Apotex Inc, a Canada-based global health company, announced on Friday that Health Canada has approved Apo-Semaglutide InjectionTM, a generic equivalent of Ozempic (semaglutide injection).Apotex is the first Canada-based pharmaceutical co...
Vanda Pharmaceuticals NEREUS (tradipitant) commercially available for Motion sickness in US
4 May 2026 - Vanda Pharmaceuticals Inc (Nasdaq: VNDA), a Washington D.C.-based biopharmaceutical company, announced on Friday that NEREUS (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by m...
Spinogenix to present tazbentetol preclinical results in glaucoma and diabetic retinopathy models at ARVO 2026
4 May 2026 - Spinogenix Inc, a California-based clinical-stage biopharmaceutical company announced on Sunday that it will present the results of two new preclinical studies demonstrating the neuroprotective effects of tazbentetol (SPG302) in glaucoma...
Specialised Therapeutics' chronic graft-versus-host disease therapy approved in Australia
4 May 2026 - Australia-based independent biopharmaceutical company Specialised Therapeutics (ST) announced on Sunday that its NIKTIMVO (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administration (TGA) for the treatment...